Research-only: Calm + Focus (Selank + Semax)
Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.
SelankLowDaily • Lyophilized • Claims of anxiolysis come from limited clinical literature; quality varies.1mg
Clinical literature reports anxiolytic effects in patient cohorts, but study designs & reporting standards vary & limit certainty.
Selank showed pronounced anxiolytic & mild nootropic effects compared with phenazepam; the anxiolytic effect persisted for approximately one week after the last dose. Methodology reflects older Russian clinical reporting standards, limiting generalizability.
10mg
Mechanistic literature suggests Semax may influence hippocampal BDNF/trkB-related signaling; this is supportive biology rather than definitive clinical efficacy.
An independent cognitive vitality report reviews Semax & emphasizes limited high-quality human clinical evidence for cognitive outcomes.
Animal work demonstrates that Semax activates transcription of neurotrophins (BDNF, TrkC, TrkA) & suppresses pro-inflammatory gene expression after cerebral ischemia; this is not direct proof of cognitive improvement in healthy humans.
Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.
Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.
Similar community stacks
If this is close but not quite right, start from a similar stack rather than from zero.
Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).
Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.
Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.